Fig. 4: aCD40 and ICB results in a vaccine effect and rejection of a secondary tumor rechallenge. | npj Breast Cancer

Fig. 4: aCD40 and ICB results in a vaccine effect and rejection of a secondary tumor rechallenge.

From: Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer

Fig. 4: aCD40 and ICB results in a vaccine effect and rejection of a secondary tumor rechallenge.

A Proportions of circulating effector memory (CD44 + CD62L-), central memory (CD44 + CD62L+), and naïve (CD44-CD62L-) CD4+ (left) and CD8+ (right) in blood, 3 months post treatment induced tumor clearance (n = 5–6, data representative of 2 experiments with similar results). B Secondary Brpkp110 tumor rechallenge of naïve and previously Brpkp110 tumor-bearing mice cured after aCD40 + ICB, at least 2 months post primary tumor clearance (n = 12–14, data representative of 3 experiments with similar results). C Control and rechallenge tumor growth in T cell sufficient (n = 6–12) and T cell depleted hosts (n = 12–14, data representative of 2 experiments with similar results). D Brpkp110 tumor growth curves in intra-tumoral (IT) vehicle (control) and IT aCD40 treated hosts. aCD40 administered tumors denoted as aCD40 IT and contralateral untreated tumors denoted as CD40 IT Distant (n = 9–12, data representative of 2 experiments with similar results). E Brpkp110 tumor growth curves in intra-tumoral (IT) vehicle (control) and IT or intraperitoneal (IP) aCD40 or ICB received hosts (n = 4–9, data representative of 2 experiments with similar results). Data: (A) median, (C–E) mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Back to article page